Clinical trials: Spine Osteoarthritis
Ankylosing Spondylitis
Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study
This study will explore how genes may influence the severity of ankylosing spondylitis, a form of arthritis that affects the spine.
- Trial name
- NCT00056719
- Where
- United States
- Volunteers
- 299 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Nonradiographic Axial Spondyloarthritis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis
The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active nonradiographic axial spondyloarthritis…
- Trial name
- BE MOBILE 1 (NCT03928704)
- Testing
- Bimekizumab
- Where
- 83 sites in United States, Belgium and 11 more
- Volunteers
- 274 people
- Sponsor
- UCB Biopharma SRL
Chronic Hepatitis B, Rheumatoid Arthritis
Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα
Analysis of effect of anti-TNFα treatment on HBV reactivation among patients with systemic rheumatic disease, especially rheumatoid arthritis
- Conditions
- Chronic Hepatitis B, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01694264
- Testing
- Entecavir
- Where
- 22 sites in South Korea
- Volunteers
- 43 people
- Sponsor
- Seoul National University Hospital
Axial Spondyloarthritis
A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis
The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized…
- Trial name
- NCT03129100
- Testing
- Ixekizumab
- Where
- 127 sites in United States, Argentina and 21 more
- Volunteers
- 773 people
- Sponsor
- Eli Lilly and Company
Axial Spondyloarthritis
Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis
The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SCT650C in patients with Axial Spondyloarthritis
- Trial name
- NCT06197009
- Testing
- SCT650C
- Where
- Turkey (Türkiye)
- Volunteers
- 168 people
- Sponsor
- Sinocelltech Ltd.
Psoriatic Arthritis
Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment [WPAI])
A special investigation (post marketing observational study [PMOS]/non-mandatory) of HUMIRA® in Japanese psoriatic arthritis patients who are engaged in paid work.
- Trial name
- NCT02414633
- Volunteers
- 148 people
- Sponsor
- AbbVie
Arthritis, Arthritis, Rheumatoid
Cellular and Molecular Analysis of Synovial Tissue of Patients With Arthritis
This study aims to study the inflammatory response in various forms of arthritis.
- Conditions
- Arthritis, Arthritis, Rheumatoid, Osteoarthritis, Spondyloarthritis
- Trial name
- NCT06737952
- Volunteers
- 90 people
- Sponsor
- University Hospital, Basel, Switzerland
Axial Spondyloarthritis
Assessing the Feasibility of the Patient-Reported Outcomes Based Model for Community Care of Patients With Axial Spondyloarthritis Via a Type 1 Pilot Hybrid Effectiveness-Implementation Trial Using the RE-AIM Framework
The goal of this clinical trial is to facilitate the implementation of PROMs-based care for patients with axial spondyloarthritis.
- Trial name
- PROMise-Pilot (NCT06968247)
- Testing
- PROMise Model of Care
- Where
- Singapore
- Volunteers
- 70 people
- Sponsor
- Singapore General Hospital
Arthritis, Rheumatic Diseases
Efficacy of Modification of Lifestyle in the Treatment of Ankylosing Spondylitis: a Pilot Study
Axial spondyloarthritis (axSpA) is a chronic inflammatory immune disorder with a global prevalence that ranges from 20 to 160 cases per 10000 individuals.
- Conditions
- Arthritis, Rheumatic Diseases, Autoimmune Diseases
- Trial name
- EMLAS (NCT05666115)
- Testing
- Probiotic group, Exercise group
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Camilo Jose Cela University
Spondyloarthropathy
A Study of the MASEI in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis
This is a randomized, double-blind, multicentral clinical trial to investigate the efficacy of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc fusion protein injection (Yisaipu®) in the treatment of peripheral…
- Trial name
- NCT02960035
- Testing
- 50mg etanercept, 25mg etanercept
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Psoriasis, Psoriatic Arthritis
Study of Psoriatic Arthritis
This study will examine the genetic and immune factors involved in the cause and development of psoriatic arthritis-a disease of both the skin and joints.
- Trial name
- NCT00001420
- Where
- United States
- Volunteers
- 999 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Ankylosing Spondylitis, Participation, Patient
Turkish Version of the Adapted Social Role Participation Questionnaire
Participation, as defined by the International Classification of Functioning, Disability, and Health (ICF), refers to "engagement in a life situation" and is a key component of functional health beyond physical impairments or…
- Trial name
- NCT06948968
- Testing
- Social Role Participation Questionnaire
- Where
- Turkey (Türkiye)
- Volunteers
- 129 people
- Sponsor
- Kocaeli University
Psoriatic Arthritis
GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA
An investigator-initiated double-blind, parallel-group randomised controlled trial of Methotrexate versus GOLimumab and Methotrexate in very early PsA using clinical and whole body MRI outcomes.
- Trial name
- GOLMePsA (NCT04108468)
- Testing
- Methotrexate, Golimumab
- Where
- United Kingdom
- Volunteers
- 84 people
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Arthritis, Psoriatic
Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy
The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with active Psoriatic Arthritis and an inadequate response to Nonsteroidal anti-inflammatory drugs (NSAIDs) and…
- Trial name
- NCT01490450
- Testing
- BMS-945429
- Where
- 49 sites in United States, Argentina and 11 more
- Volunteers
- 165 people
- Sponsor
- CSL Behring
Ankylosing Spondyloarthritis
Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis
Apremilast is a new, orally available, small molecule drug that specifically inhibits phosphodiesterase 4 (PDE4), an enzyme that modulates inflammatory cytokines.
- Trial name
- POSTURE (NCT01583374)
- Testing
- Apremilast tablet 20 mg, Apremilast tablet 30 mg BID
- Where
- 103 sites in United States, Australia and 16 more
- Volunteers
- 490 people
- Sponsor
- Amgen
Psoriatic Arthritis (PsA)
Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants
The purpose of this study is a long-term, observational study of Abatacept in patients with Psoriatic Arthritis, a chronic inflammatory disorder.
- Trial name
- ALTEA (NCT03419143)
- Where
- Germany
- Volunteers
- 190 people
- Sponsor
- Bristol-Myers Squibb
Ankylosing Spondylitis
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy
The primary objective of this study is to evaluate the effect of filgotinib versus placebo on signs and symptoms of active ankylosing spondylitis (AS), evaluated by Assessment of SpondyloArthritis international Society 40%…
- Trial name
- SEALION2-NAÏVE (NCT04483700)
- Testing
- Filgotinib
- Sponsor
- Gilead Sciences
Covid19, Inflammatory Rheumatism
Selection of Patients With Chronic Inflammatory Rheumatism Requiring Management During the COVID-19 Pandemia
The project proposes to evaluate a strategy for prioritizing teleconsultation for patients with chronic inflammatory rheumatic diseases during the COVID-19 pandemia.
- Conditions
- Covid19, Inflammatory Rheumatism, Rheumatoid Arthritis, Spondyloarthritis
- Trial name
- SePaRIC (NCT04806867)
- Testing
- SePaRIC-Covid19 cohort
- Where
- France
- Volunteers
- 918 people
- Sponsor
- University Hospital, Limoges
Spondylitis, Ankylosing
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
The purpose of the study is to evaluate the efficacy and tolerability of two doses of etoricoxib compared to naproxen in the treatment of ankylosing spondylitis (AS).
- Trial name
- NCT01208207
- Testing
- Part I - etoricoxib 60 mg, Part I - etoricoxib 90 mg, Part I- naproxen 1000 mg
- Volunteers
- 1,015 people
- Sponsor
- Organon and Co
Psoriatic Arthritis
A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab
The primary purpose of this study is to describe the Psoriatic Arthritis (PsA) participant profiles depending on whether their disease is managed by a dermatologist or by a rheumatologist in routine practice.
- Trial name
- PROUST (NCT03336281)
- Testing
- Ustekinumab
- Where
- France
- Volunteers
- 221 people
- Sponsor
- Janssen Cilag S.A.S.